Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine Therapy for Vaso-Occlusive Events in Children With Severe Sickle Cell Disease
NCT02447874Phase 2Recruiting
- Sponsor
- Emory University
- Start
- May 2015
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arginine in sickle cell disease (SCD), sponsored by Emory University. Started May 2015; status: recruiting.
02
Drugs
arginine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02447874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447874.